Iscalimab Combined With Transient Tesidolumab Prolongs Survival in Pig‐to‐Rhesus Monkey Renal Xenografts
Xenotransplantation · 2024
DOI: 10.1111/xen.12880 ↗Kurz gefasst
Fachartikel in der Zeitschrift Xenotransplantation, 2024. Verfasst von Andrew B Adams und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Minnesota School of Medicine, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Macaca mulatta, Transplantation, Heterologous, Graft Survival, Kidney Transplantation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH NIAID, Novartis.
Abstract (Originalsprache)
Objective
To evaluate the clinically relevant anti‐CD40 antibody iscalimab for baseline immunosuppression in a preclinical pig‐to‐rhesus renal xenograft model. Summary Background Data CD40/CD40L co‐stimulation blockade‐based immunosuppression has been more successful than calcineurin‐based protocols in prolonging xenograft survival in preclinical models.
Methods
GGTA1 knockout/CD55 transgenic pig kidneys were transplanted into rhesus monkeys ( n = 6) receiving an iscalimab‐based immunosuppressive regimen.
Results
Two grafts were lost early (22 and 26 days) because of ectatic donor ureters with otherwise normal histology. The other recipients survived 171, 315, 422, and 439 days with good renal function throughout the posttransplant course. None of the recipients experienced serious infectious morbidity.
Conclusions
It may be reasonable to evaluate an iscalimab‐based immunosuppressive regimen in clinical renal xenotransplantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, University of Minnesota School of Medicine, Minneapolis, Minnesota, USA.
- Department of Surgery, Emory University School of Medicine, Atlanta, Georgia, USA.
- Department of Surgery, University of Miami School of Medicine, Miami, Florida, USA.
- Makana Therapeutics, Miami, Florida, USA.
ORCID-Profile: Christopher Burlak, Matt Tector, Alfred J Tector
Förderung
- NIH NIAID
- Novartis
Zitieren
APA
Adams, A. B., Faber, D., Lovasik, B. P., Matar, A. J., Kim, S. C., Burlak, C., Tector, M., & Tector, A. J. (2024). Iscalimab Combined With Transient Tesidolumab Prolongs Survival in Pig‐to‐Rhesus Monkey Renal Xenografts. Xenotransplantation. https://doi.org/10.1111/xen.12880
Vancouver
Adams AB, Faber D, Lovasik BP, Matar AJ, Kim SC, Burlak C, et al. Iscalimab Combined With Transient Tesidolumab Prolongs Survival in Pig‐to‐Rhesus Monkey Renal Xenografts. Xenotransplantation. 2024. doi:10.1111/xen.12880
BibTeX
@article{Adams2024,
author = {Adams, Andrew B and Faber, David and Lovasik, Brendan P and Matar, Abraham J and Kim, Steven C and Burlak, Christopher and Tector, Matt and Tector, Alfred J},
title = {Iscalimab Combined With Transient Tesidolumab Prolongs Survival in Pig‐to‐Rhesus Monkey Renal Xenografts},
journal = {Xenotransplantation},
year = {2024},
doi = {10.1111/xen.12880}
}
EUVIMED